STOCKHOLM, 13-Mar-2019 — /EuropaWire/ — Summa Equity’s acquisition of Olink AB has been supported by EQT Credit through its Mid-Market Credit investment strategy. EQT Credit has provided a senior secured financing in support of the deal.
Olink Proteomics offers protein biomarker discovery products and services with operations in Europe and the US (Watertown). The company has been founded in 2004 and is based in Uppsala, Sweden. Olink’s patent-protected Proximity Extension Assay (PEA) technology is used to identify over 1,100 protein biomarkers, achieving both high throughput and high sensitivity samples analysis for its customers.
The Olink deal will be the 14th investment for the EQT Mid-Market Credit II and is also the 3rd Nordic investment made by fund in the last 12 months.
Paul Johnson, Partner at EQT Partners’ Credit team, Investment Advisor to EQT Credit, commented:
“Olink has developed an innovative and unique technology for multiplex protein testing. EQT Credit is excited to support Summa and the Company in achieving its full potential.”
Alexandre Hökfelt, Director at EQT Partners’ Credit team, Investment Advisor to EQT Mid-Market Credit:
“Having completed the first transaction together last year, EQT is happy to again partner with Summa on this exciting investment in Olink. We would like to thank the EQT Industrial Advisors who provided key support and valuable insights to the EQT Credit deal team throughout the due diligence process.”
EQT Credit has invested over EUR 5.5 billion in about 180 companies. The firm invests through Senior Debt, Mid-Market Credit (direct lending), Core Value and Credit Opportunities. EQT Credit is active in Europe across a wide range of sectors looking for mid-sized European businesses in need of flexible, long- term debt capital solutions. Companies can benefit from alternative funding to grow further or the deals can be private equity-led acquisitions or refinancings.